Utama › Leukemia Mieloid Akut › South Carolina › Greenville
Kajian klinikal Leukemia Mieloid Akut di Greenville, SC
10 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Greenville (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Mengambil pesertaFasa 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Greenville Memorial Hospital, Greenville
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Mengambil pesertaFasa 3
- BI-LO Charities Children's Cancer Center, Greenville
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Mengambil pesertaFasa 1/2
- Bon Secours St. Francis Cancer Center, Greenville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Mengambil pesertaFasa 1/2
- BI-LO Charities Children's Cancer Center, Greenville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Mengambil pesertaFasa 1
- Prisma Health, Greenville
Kajian Leukemia Mieloid Akut di bandar lain
- Houston, TX85 kajian
- New York City, NY51 kajian
- Boston, MA44 kajian
- Seattle, WA41 kajian
- Baldwin Park, CA40 kajian
- Columbus, OH35 kajian
- Philadelphia, PA34 kajian
- Durham, NC33 kajian
- Atlanta, GA31 kajian
- Tampa, FL29 kajian
- Chicago, IL26 kajian
- Portland, OR25 kajian
Kajian lain di Greenville
- Kanser Paru-paru Bukan Sel Kecil15 kajian
- Kanser Payudara12 kajian
- Kanser (semua jenis)9 kajian
- Obesiti9 kajian
- Kanser Paru-paru9 kajian
- Berat Badan Berlebihan8 kajian
- Kanser Prostat7 kajian
- Kanser Kolorektal7 kajian
- Kanser Perut6 kajian
- Penyakit Arteri Periferi5 kajian
- Limfoma Burkitt5 kajian
- Melanoma5 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.